A risk-benefit assessment of pharmacological treatments for panic disorder.
Panic disorder, a psychiatric disorder characterised by frequent panic attacks, is the most common anxiety disorder, affecting 2 to 6% of the general population.
No one line of treatment has been found to be superior, making a risk-benefit assessment of the treatments available useful for treating patients.
Choice of treatment depends on a number of issues, including the adverse effect profile, efficacy and the presence of concomitant syndromes.
Tricyclic antidepressants (TCAs) are beneficial in the treatment of panic disorder.
They have a proven efficacy, are affordable and are conveniently administered.
Adverse effects, including jitteriness syndrome, bodyweight gain. anticholinergic effects and orthostatic hypotension are commonly associated with TCAs, but can be managed successfully.
Selective serotonin (5-hydroxytryptamine : 5HT) reuptake inhibitors are also potential first line agents and are well tolerated and effective, with a favourable adverse effects profile.
There is little risk in overdose or of anticholinergic effects.
Adverse effects include sedation. dyspepsia and headache early in treatment, and sexual dysfunction and increased anxiety, but these can be effectively managed with proper dosage escalation and management.
Benzodiazepines are an effective treatment, providing short-term relief of panic-related symptoms.
Patients respond to treatment quickly, providing rapid relief of symptoms. (...)
Mots-clés Pascal : Antidépresseur, Composé tricyclique, Chimiothérapie, Traitement, Panique, Homme, Acide valproïque, Benzodiazépine dérivé, Inhibiteur recapture, Sérotonine, IMAO, Psychothérapie, Analyse risque, Analyse avantage coût, Economie santé, Article synthèse, Toxicité, Trouble anxieux, Ohio, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Antidepressant agent, Tricyclic compound, Chemotherapy, Treatment, Panic, Human, Valproic acid, Benzodiazepine derivatives, Reuptake inhibitor, Serotonin, MAO inhibitor, Psychotherapy, Risk analysis, Cost benefit analysis, Health economy, Review, Toxicity, Anxiety disorder, Ohio, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0351550
Code Inist : 002B02B02. Création : 27/11/1998.